Revlimid Combination Granted Priority Review for Myeloma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The FDA has given priority review status to Celgene Corporation's supplemental new drug application for lenalidomide (Revlimid) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.

SUMMIT, New Jersey—The FDA has given priority review status to Celgene Corporation's supplemental new drug application for lenalidomide (Revlimid) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. In two large phase III trials in previously treated myeloma patients, North American Trial MM-009 and International Trial MM-010, the combination showed safety and efficacy. Revlimid, a derivative of thalidomide (Thalomid), is an immunomodulatory drug. It previously received FDA approval for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content